Patents by Inventor Joseph G. Reynolds

Joseph G. Reynolds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for treating HER2-positive cancers
    Patent number: 9913901
    Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 13, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
  • COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES
    Publication number: 20170258903
    Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 14, 2017
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Christopher W. Espelin, Elena Geretti, Bart S. Hendriks, Victor Moyo, Joseph G. Reynolds, Thomas Wickham
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS
    Publication number: 20170189335
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: January 18, 2017
    Publication date: July 6, 2017
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
    Patent number: 9610249
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: April 4, 2017
    Assignee: Merrimack Pharmaceuticals. Inc.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Combination Therapies for Treating Her2-Positive Cancers that are Resistant to Her2-Targeted Therapies
    Publication number: 20170080087
    Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: CHRISTOPHER ESPELIN, ELENA GERETTI, VICTOR MOYO, JOSEPH G. REYNOLDS, THOMAS WICKHAM, BART S. HENDRIKS
  • COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS
    Publication number: 20170022290
    Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
    Type: Application
    Filed: May 31, 2016
    Publication date: January 26, 2017
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: VICTOR MOYO, BART S. HENDRIKS, THOMAS WICKHAM, ELENA GERETTI, JOSEPH G. REYNOLDS, CHRISTOPHER W. ESPELIN
  • COMBINATION THERAPY FOR TREATING HER2-POSITIVE CANCERS
    Publication number: 20160250328
    Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
    Type: Application
    Filed: December 3, 2013
    Publication date: September 1, 2016
    Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
  • COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES
    Publication number: 20160045596
    Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
    Type: Application
    Filed: August 5, 2015
    Publication date: February 18, 2016
    Inventors: Elena Geretti, Victor Moyo, Joseph G. Reynolds, Thomas Wickham
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS
    Publication number: 20160038416
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: August 20, 2015
    Publication date: February 11, 2016
    Inventors: JOSEPH G. REYNOLDS, KENNETH J. OLIVIER, JR., BART S. HENDRIKS, THOMAS WICKHAM, STEPHAN KLINZ, ELENA GERETTI
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS
    Publication number: 20160038417
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 11, 2016
    Inventors: JOSEPH G. REYNOLDS, Kenneth J. Olivier, Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
    Patent number: 9226966
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: January 5, 2016
    Assignee: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLIN CHEMOTHERAPEUTIC AGENTS
    Publication number: 20140023698
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: June 6, 2013
    Publication date: January 23, 2014
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti